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AbstrACt
Introduction With an increasing prevalence of citizens of 
older age and with overweight, the health issues related 
to knee osteoarthritis (OA) will intensify. Weight loss is 
considered a primary management strategy in patients 
with concomitant overweight and knee OA. However, there 
are no widely available and feasible methods to sustain 
weight loss in patients with overweight and knee OA. The 
present protocol describes a randomised controlled trial 
evaluating the efficacy and safety of the glucagon-like 
peptide-1 receptor agonist liraglutide in a 3 mg/day dosing 
in patients with overweight and knee OA.
Methods and analysis 150 volunteer adult patients with 
overweight or obesity and knee OA will participate in a 
randomised, double-blind, placebo-controlled, parallel-
group and single-centre trial. The participants will partake 
in a run-in diet intervention phase (week −8 to 0) including 
a low calorie diet and dietetic counselling. At week 0, 
patients will be randomised to either liraglutide 3 mg/day 
or liraglutide placebo 3 mg/day for 52 weeks as an add-on 
to dietetic guidance on re-introducing regular foods and 
a focus on continued motivation to engage in a healthy 
lifestyle. The co-primary outcomes are changes in body 
weight and the Knee Injury and Osteoarthritis Outcome 
Score pain subscale from week 0 to week 52.
Ethics and dissemination The trial has been approved 
by the regional ethics committee in the Capital Region of 
Denmark, the Danish Medicines Agency and the Danish 
Data Protection Agency. An external monitoring committee 
(The Good Clinical Practice Unit at Copenhagen University 
Hospitals) will oversee the trial. The results will be 
presented at international scientific meetings and through 
publications in peer-reviewed journals.
trial registration numbers 2015-005163-16, 
NCT02905864, U1111-1171-4970
based on protocol version  V.6; 30 January 2017, 15:30 
hours
IntroduCtIon
Obesity is a serious medical condition with 
increasing incidence and prevalence world-
wide. The achievement and maintenance of 
a healthy body weight is the main strategy for 
prevention and management of obesity-re-
lated diseases.1 2 The majority of subjects with 
a successful weight loss regain weight over 
the subsequent years and the maintenance 
of a clinically significant weight loss over time 
strengths and limitations of this study
 ► This will be the first randomised controlled trial ex-
amining the efficacy and safety of daily liraglutide 
3 mg/day in patients with overweight and knee os-
teoarthritis (OA).
 ► Participants will be randomised to receive either li-
raglutide 3 mg/day or liraglutide placebo 3 mg/day 
for 52 weeks as an add-on to dietetic guidance.
 ► The selected primary and secondary outcomes are 
aligned with outcome measures in rheumatology 
recommendations.
 ► This trial has a strict focus on an adult population 
with clinical knee OA who can successfully go 
through an intensive dietary programme (the target 
being to lose at least 5% of their initial body weight).
 ► The trial has implication for the large number of pa-
tients impacted by overweight and knee OA.
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remains a challenge for healthcare professionals, patients 
and societies.1 
Osteoarthritis (OA) is the most common type of 
arthritis, characterised by pain and physical disability.3 In 
addition, >10% of those aged >55 years have symptom-
atic OA, primarily involving the knees.4 Due to the pivotal 
role of the knee in basic mobility and locomotion, knee 
OA is associated with significant impairments and limita-
tions to basic activities of daily living, such as walking and 
moving around, self-care and housekeeping activities, as 
well as participation in community life and recreational 
activities—all contributing to reduced quality of life and 
needs for assistance. Epidemiological data link obesity 
to the development of knee OA,5 obesity and knee OA 
share pathogenic phenotypes, and the development of 
one disease increases the risk of the other, potentially trig-
gering the onset of a vicious cycle.6
Glucagon-like peptide 1 (GLP-1) is an incretin 
hormone that stimulates endogenous insulin secretion 
in a glucose-dependent manner. GLP-1 also lowers blood 
glucagon levels, reduces gastric emptying by decreasing 
gastric motility and increases satiety. These mechanisms 
have been exploited therapeutically in the treatment of 
type 2 diabetes for more than a decade, and recently the 
satiety promoting and body weight lowering effects of 
the GLP-1 analogue liraglutide prompted the US Food 
and Drug Administration and the European Medicines 
Agency to approve liraglutide in a once-daily dose of 3 mg 
for the treatment of patients with overweight or obesity. 
Published data, investigating the use of liraglutide 3 mg/
day in a population of patients with obesity as well as 
dyslipidaemia and/or hypertension, revealed a long-term 
positive impact on both body weight and related health 
benefits.7
scientific gap
The present trial has been designed to further investi-
gate the potential of liraglutide 3 mg/day to safely induce 
and maintain long-term weight loss in patients with over-
weight or obesity and knee OA. Weight loss is strongly 
recommended as a management strategy of patients 
with concomitant overweight or obesity and knee OA, 
and improves both pain and function.8–11 However, no 
widely available and feasible means to sustain weight loss 
in patients with overweight or obesity and knee OA has 
been presented.
Hypotheses
A diet intervention combined with liraglutide 3 mg/day, 
for 52 weeks, is sufficient to induce and maintain weight 
loss and to improve knee OA-related pain symptoms. As 
such, the primary hypotheses to be tested are:
 ► In patients with overweight or obesity and knee OA, a 
diet intervention combined with liraglutide 3 mg/day 
will induce and maintain a significantly greater weight 
loss compared with a diet intervention combined 
with an identically appearing liraglutide placebo 
treatment.
 ► In patients with overweight or obesity and knee OA, 
a diet intervention combined with liraglutide 3 mg/
day will induce and maintain a significantly greater 
reduction in knee OA pain compared with a diet 
intervention combined with an identically appearing 
liraglutide placebo treatment.
objectives
The primary objectives are to establish the efficacy and 
safety of a diet intervention combined with liraglutide 
3 mg/day, or placebo, in inducing and maintaining 
weight loss over 52 weeks and in improving symptomatic 
knee pain.
MEtHods And AnAlysIs
trial design
The trial is designed as a single-centre, randomised, place-
bo-controlled, participant, investigator and outcome 
assessor blinded, parallel-group trial. It contains three 
periods. Participants will initially be enrolled in an 8-week 
intensive dietary intervention (IDI) period. If success-
fully achieving a weight loss of minimum 5% during 
this period participants will continue with a tapering 
dietary intervention (TDI) for 8 weeks (week 0–8) and be 
randomised to receive either liraglutide 3 mg/day or iden-
tically appearing placebo throughout the 52-week main 
trial period (week 0–52). The trial will be completed by a 
12-week postinterventional observation period (figure 1).
trial conduct
Participants will be recruited within 12 months from the 
OA outpatients' clinic at the Parker Institute at Copen-
hagen University Hospital, Bispebjerg and Frederiksberg. 
General practitioners and collaborating clinical hospital 
departments in the Capital Region will be informed 
about the possibility to refer patients to the project. In 
addition, the trial will be advertised in newspapers and on 
the Parker Institutes website ( www. parkerinst. dk).
Potential study participants will initially partake in a 
motivational assessment including an interview in which 
the nature of the initial IDI is explained together with a 
description of the overall study, a thorough outline of the 
interventions and visits, and a session in which the inves-
tigator addresses any questions the potential participant 
may have. The study will not use any standardised scoring 
system to assess motivation, but during the interview the 
investigator will assess the individual’s motivation for 
weight loss through both the IDI period and the subse-
quent participation in the randomised part of the study.
Before enrolment takes place, potential participants will 
be provided with written and verbal information about 
the trial and the procedures involved, in accordance 
with local requirements. Potential participants will have 
the opportunity to ask questions and have ample time to 
consider their participation. Following the signature of 
the informed consent form participants will be enrolled 
in the 8-week IDI period.
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The IDI period comprises a supervised dietary weight 
loss programme in which participants receive a hypo-
caloric formula diet containing 800–1000 kcal/day. 
The formula diet consists of ready-to-use meal bars 
and powders to mix with water to make shakes, soups 
or porridge. The weight loss programme consists of an 
8-week period with full meal replacement according to 
a standard liquid energy intake protocol. To facilitate 
adherence to the programme, patients will be scheduled 
for weekly facility-based group sessions with six to eight 
patients led by a dietician. The recommendations for 
daily nutrient intake will be met during this period.
Participants achieving a weight loss ≥5% during the 
IDI will be randomised to daily receive either liraglutide 
3 mg/day or an identical placebo throughout the subse-
quent 52-week main trial period.
The initial 8 weeks of the main trial period consist of an 
8-week TDI period (week 0–8) focusing on a partial re-in-
troduction of regular meals in combination with formula 
diet products. In this period, all participants (irrespective 
of randomisation) will be scheduled to meet for group 
sessions led by a dietician every 2 weeks. No dietary 
consultancies will be offered from the trial after week 8, 
but to prevent attrition patients will be offered one to two 
daily meal replacements with a formula diet from week 8 
to 52 to be administered by themselves. Participants will 
be instructed to aim for an intake of 1200 kcal/day from 
week 0 to 8 and for an intake of 1500 kcal/day from week 
8 and onwards.
For the main trial period (drug intervention period 
running from week 0 to 52), participants will be 
randomised at week 0 to one of the two experimental 
arms described below:
 ► Liraglutide, 3 mg/day
 – Arm description: subjects will be up-titrated to lira-
glutide 3 mg once daily and stay on that dose for 
the remainder of the 52-week drug intervention 
period.
 – Drug: liraglutide 3 mg once daily administered in 
a 6 mg/mL, 3 mL pen for subcutaneous injection.
 – Dose escalation/titration scheme: initial dosage of 
0.6 mg/day, escalated biweekly by 0.6–3 mg/day 
over a total of 8 weeks. Visits will be conducted at 
weeks 0, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 
48 and 52.
 ► Liraglutide placebo, 3 mg/day
 – Arm description: subjects will be up-titrated to lira-
glutide 3 mg placebo once daily and stay on that 
dose for the remainder of the 52-week drug inter-
vention period.
 – Drug: liraglutide 3 mg placebo once daily adminis-
tered in a 6 mg/mL drug equivalent volumes, 3 mL 
pen for subcutaneous injection.
 – Dose escalation scheme: initial dosage of a 0.6 mg drug 
equivalent volume per day, escalated biweekly by a 
0.6 mg drug equivalent volume per day to a 3 mg 
drug equivalent volume per day over a total of 8 
weeks. Visits will be conducted at weeks 0, 2, 4, 6, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52.
Research nurses with experience in trials involving 
self-administered injections will instruct participants in 
the use of pens, and the materials used to support the 
Figure 1 Trial design. 
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verbal instructions will be the publicly available materials 
produced by Novo Nordisk for liraglutide. Dose escala-
tion will be based on safety as well as tolerability and if 
dose escalation is not feasible, then delayed increments 
are allowed. Subjects will be maintained at the highest 
tolerated dose level and the reduction of the achieved 
maintenance dose will lead to patient discontinuation.
The trial will end when the last patient has i) completed 
the last visit as well as the 12-week postinterventional 
observation period, ii) prematurely discontinued the 
intervention or iii) withdrawn from the trial, whichever 
comes last.
For all potential trial participants, the following will 
be recorded: number of individuals initially assessed for 
eligibility, number excluded before enrolment (including 
reasons for non-eligibility), number enrolled, number 
randomised and number withdrawn/dropped out during 
the trial (including reasons for withdrawal or exclusion). 
From allocation and onwards study personnel will assess 
the use of study medication to evaluate adherence.
Prior to the start of the study, the sponsor-investigator 
will ensure that the other investigators are familiar with 
the protocol, electronic case report forms (eCRFs) and 
other study documents and procedures. The sponsor-in-
vestigator will be visited by the monitor prior to trial 
commencement and thereafter on a regular basis. The 
monitor will check trial procedures, including safety 
assessments, drug handling, data recording and complete 
source data verification procedures.
Visits, assessments and procedures will take place as 
visualised in table 1.
trial site
The trial will be conducted at the Parker Institute 
at Copenhagen University Hospital, Bispebjerg and 
Frederiksberg. The Parker Institute is a well-established 
research institute and clinical department with secre-
tariat, data managers and Good Clinical Practice (GCP) 
educated healthcare professionals such as physicians, 
trained specialists in rheumatology and radiology, nurses 
and laboratory technicians. Moreover, access to other 
departments and specialities within the hospital is avail-
able on request if deemed necessary.
trial population
To be enrolled in this trial, the following eligibility criteria, 
assessed at screening, must be met:
Inclusion criteria
 ► Informed consent obtained.
 ► Clinical diagnosis of knee OA (American College of 
Rheumatology criteria) with early to moderate radi-
ographic changes (Kellgren-Lawrence [KL] grades 1, 
2 or 3).
 ► Age≥18 years and <75 years.
 ► Body mass index (BMI) ≥27 kg/m2.
 ► Stable body weight during the previous 3 months 
(<5 kg self-reported weight change).
 ► Motivated for weight loss.
 ► Achieved at least 5% weight loss during the initial 
8-week IDI (assessed at allocation visit; T0).
Exclusion criteria
 ► Ongoing participation, or participation within the last 
3 months, in an organised weight loss programme (or 
within the last 3 months).
 ► Current or history of treatment with medications that 
may cause significant weight gain for at least 3 months 
before this trial.
 ► Current use or use within 3 months before this trial 
of GLP-1 receptor agonist, pramlintide, sibutramine, 
orlistat, zonisamide, topiramate or phentermine.
 ► Type 1 diabetes.
 ► Type 2 diabetes treated with glucose-lowering drugs 
other than metformin.
 ► Alloplasty in target knee joint (most symptomatic 
knee at screening).
 ► End-stage disease in target knee joint (KL grade 4).
 ► Immuno-inflammatory disease.
 ► Chronic widespread pain.
 ► Pregnancy or insufficient anticonception therapy for 
female fertile patients.
 ► Breast feeding.
 ► Estimated glomerular filtration rate <60 mL/
min/1.73 m2.
 ► Alanine aminotransferase (ALT) or aspartate 
aminotransferase>3×above upper normal range.
 ► Elective surgery scheduled during the trial duration 
period, except for minor surgical procedures.
 ► Surgical procedures such as arthroscopy or injections 
into a knee within 3 months prior to enrolment.
 ► Previous surgical treatment for obesity (excluding 
liposuction >1 year before trial entry).
 ► Thyroid-stimulating hormone outside of the range of 
0.4–6.0 mIU/L.
 ► Obesity secondary to endocrinological or eating 
disorders, or to treatment with medicinal products 
that may cause weight gain.
 ► Family or personal history of medullary thyroid carci-
noma or multiple endocrine neoplasia type 2.
 ► Inflammatory bowel disease.
 ► Congestive heart failure, New York Heart Association 
class III–IV.
 ► Diabetic gastroparesis.
 ► History of or current diagnosis of pancreatitis (acute 
and/or chronic) or pancreatic cancer.
 ► History of cancer with the exception of in situ malig-
nancies of the skin or cervix uteri.
 ► History of major depressive disorder, a Patient Health 
Questionnaire-9 (PHQ-9) score of >15 or a history of 
other severe psychiatric disorders or diagnosis of an 
eating disorder.
 ► Subjects with a lifetime history of a suicide attempt 
or history of any suicidal behaviour within the past 
month before entry into the trial.
 ► Inability to speak Danish fluently.
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 ► A mental state impeding compliance with the 
programme.
 ► Use of opioids or similar strong analgesics.
 ► Allergic reactions to the active ingredients of Saxenda, 
such as hypotension, palpitations, dyspnoea and 
oedema.
data collection
Patients will take part in a series of examinations and tests 
throughout the study, as mentioned below.
Knee Injury and Osteoarthritis Outcome Score
The Knee Injury and Osteoarthritis Outcome Score 
(KOOS) is designed to assess health-related quality of life 
(HRQoL) in patients with knee injuries and knee OA.12 
The KOOS consists of 42 items covering five domains, 
namely, pain, symptoms, activities of daily living, sports 
and recreation and knee-related QoL. A normalised 
score is calculated for each domain with 100 indicating 
no symptoms and functional impairment and zero indi-
cating extreme symptoms and functional impairment.
Western Ontario and McMaster Universities Arthritis Index
Western Ontario and McMaster Universities Arthritis 
Index (WOMAC) is a disease-specific questionnaire 
designed to assess pain, stiffness and physical function 
in patients with hip and/or knee OA.13 It consists of 24 
items divided into three subscales concerning pain, stiff-
ness and physical function. Higher scores on the WOMAC 
indicate worse pain, stiffness and functional limitations.
Intermittent and Constant Osteoarthritis Pain Questionnaire
The Intermittent and Constant Osteoarthritis Pain 
(ICOAP) is a diagnosis-specific 11-item questionnaire 
designed to assess the pain experience within the last 
week among people suffering from knee and hip OA.14 
The questionnaire is divided into two domains, a 5-item 
scale for constant pain and a 6-item scale for intermittent 
pain. Normalised scores, for the two subscales and for 
the total pain score, ranges from zero (no pain) to 100 
(extreme pain).
Columbia Suicide Severity Rating Scale
The Columbia Suicide Severity Rating Scale (C-SSRS) is a 
detailed questionnaire assessing both suicidal behaviour 
and suicidal ideation. Four constructs are assessed.15 The 
first is the severity of ideation, rated on a 5-point ordinal scale. 
The second is the intensity of ideation subscale comprising 
five items each rated on a 5-point ordinal scale. The third 
is the behaviour subscale, which is rated on a nominal scale. 
And the fourth is the lethality subscale, which is rated on a 
6-point ordinal scale, and if actual lethality is zero, poten-
tial lethality of attempts is rated on a 3-point ordinal scale. 
The Baseline-Screening version will be employed to assess 
inclusion/exclusion criteria and to provide a pretreat-
ment assessment at baseline. On all subsequent visits, the 
Since Last Visit version will be used.
Patient Health Questionnaire
The PHQ-9 is a diagnostic tool for mental health disor-
ders.16 The PHQ-9 is the depression subscale of the 
PHQ and contains nine questions related to depression 
disorder symptoms during the past 14 days. The answer 
categories are based on a 4-point response scale and the 
summed PHQ-9 score can range from zero to 27. A score 
of ≥15 is considered an indication of moderately severe or 
severe depression.
Binge Eating Scale
The Binge Eating Scale (BES) is a self-report instrument 
that assesses the behavioural and emotional/cogni-
tive symptoms associated with binge eating.17 The BES 
comprises 16 items assessing key behavioural (eg, rapid 
eating, eating large amounts of food) and affective/
cognitive symptoms (eg, guilt, feeling out of control or 
unable to stop eating) that precede or follow a binge. 
Each item contains three to four statements that are 
weighted response options, which reflect a range of 
severity for each characteristic. Participants are asked to 
select the statement that best describes their experience. 
The scale's possible total scores range from zero to 46, 
with higher scores indicating more severe binge eating 
symptoms.
outcome Measures in rheumatoid Arthritis Clinical trials/
osteoarthritis research society International (oMErACt-
oArsI) responder criteria
The Outcome Measures in Rheumatoid Arthritis Clin-
ical Trials/Osteoarthritis Research Society International 
responder criteria include a composite index based on 
pain, function and patient global.18 For the purpose of 
assessing this, we will employ three questions regarding 
knee pain, physical function and the patients’ global 
assessment of disease impact on their daily life. The 
answers to each of these questions are given on 100 mm 
visual analogue scales (VAS).
To assess pain, the patients are asked to indicate 
‘the degree of knee pain in your daily life’ (VAS-pain). 
The anchors on the 100 mm VAS are 0=‘no pain’ and 
100=‘worst imaginable pain’. To assess physical function, 
the patients are asked to indicate ‘the degree of physical 
impairment of your knee in your daily life’ (VAS-func-
tion). The anchors on the 100 mm VAS are 0=‘no impair-
ment’ and 100=‘worst imaginable impairment’. To assess 
the patients’ global assessment of disease impact on their 
daily life, the patients are asked to indicate ‘the overall 
impact of your knee OA on your daily life’ (VAS-global). 
The anchors on the 100 mm VAS are 0=‘no impact’ and 
100=‘worst imaginable impact’.
Categorisation as a responder requires an improvement 
in the above-mentioned pain or function VAS scores of at 
least 50% and an absolute change of 20 mm. Alternatively, 
a response can be achieved by meeting at least two of 
the following three criteria: (1) an improvement of 20% 
and an absolute change of 10 mm in VAS-pain, (2) an 
improvement of 20% and an absolute change of 10 mm 
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in VAS-function or (3) an improvement of 20% and an 
absolute change of 10 mm in VAS-global.
Impact of Weight on Quality of life-lite
The Impact of Weight on Quality of Life-Lite (IWQoL-
Lite) is a 31-item, self-report, obesity-specific measure of 
HRQoL that consists of a total score and scores on each 
of five scales: physical function, self-esteem, sexual life, 
public distress and work.19 Scores range from zero to 100, 
where 100 represent the best HRQoL and zero represents 
the worst.
Treatment-Related Impact Measure-Weight
The TRIM-Weight is an obesity treatment-specific 
patient-reported outcomes measure designed to assess 
the key impacts of prescription antiobesity medication 
and be applicable to the wide range of prescription 
medications currently available.20 The TRIM-Weight is 
based on 22 items within seven thematic domains related 
to a patient's experience with a weight loss medication: 
i) satisfaction in terms of weight loss, ii) the burden of 
taking the medication, iii) satisfaction in terms of appe-
tite-control, iv) the impact of weight stabilisation, mood 
swings or tiredness, v) convenience, vi) discomfort and 
vii) impact on social aspects, productiveness and relation-
ships. All items are scored on anchored rating scales with 
five levels of response (1–5) in which higher scores indi-
cate better quality of life.
Short Form 36
The Short Form 36 (SF-36) is a generic, short-form 
health status questionnaire composed of 36 questions 
within eight multi-item domains assessing physical func-
tion, social function, role-emotional, role-physical, bodily 
pain, general health, mental health and vitality.21 These 
can be combined into two summary scores (physical and 
mental health summary scores). For each summary score, 
the ordinal scores are transformed to a linear zero to 100 
scale; zero indicating the least favourable health state and 
100 indicating the best state of health.
Anthropometrics
Waist circumference will be measured mid-way between 
the lower rib margin and the iliac crest, while hip circum-
ference will be measured at the point over the buttocks 
yielding the maximum circumference. Waist and hip 
circumferences will be measured to the nearest 1 cm. All 
anthropometric measurements will be taken in accor-
dance with the WHO report on measuring obesity.
Height without shoes will be measured using a stadiom-
eter and rounded to the nearest 1 cm.
Body weight will be measured to the nearest 0.1 kg 
with a decimal weighing scale (TANITA BW-800, Tanita 
Europe BV Hoogoorddreef 56e, 1101BE Amsterdam, 
The Netherlands), with participants fasting and wearing 
underwear or light clothing, only.
The BMI (kg/m2) will be calculated from body weight 
and height.
Blood samples
Standard biochemistry: C reactive protein (CRP), ALT, 
calcium, creatinine, potassium, sodium, low-density 
lipoprotein (LDL), high-density lipoproteins (HDL), 
triglycerides (TG) and total cholesterol (TC). Haema-
tology: haemoglobin, leucocytes, differential cell count 
and thrombocytes. Glucose metabolism: haemoglobin A1c 
(HbA1c) and fasting plasma glucose (FPG).
Radiography
Radiographic examinations include standard clinical 
semi-flexed weight-bearing posterior-anterior radio-
graphs of both knees. During the examination, patients 
will be facing the plate of the radiography equipment 
with the knees touching the cassette holder or a reclining 
table top. The radiography plate or cassette holder is 
placed so that the centre of the film will be at the level 
of the patient’s tibiofemoral joint line. The radiography 
beam is centred between the knees with a 10 degrees 
cranio-caudal angle and the body weight will be distrib-
uted equally between the two legs. The radiographs will 
be assessed by use of the KL grading system; a categorical 
grading scale of knee OA going from 0 to 4 by means of 
an evaluation of osteophytes, joint space narrowing, scle-
rosis and altered bone shapes.
Vitals signs
Blood pressure (BP), systolic and diastolic, will be 
measured with the patient in sitting position with the 
legs uncrossed and the back and arm supported. Patients 
resting pulse will be measured following a resting period 
of 5 min in a sitting position with the legs uncrossed and 
the back and arms supported. Patients will be instructed 
to avoid caffeine, smoking and physical activity within 
30 min prior to both of these measurements.
Visit schedule
outcomes
Patient characteristics
Height, age, gender and KL grading will be collected and 
reported as patient characteristics.
Co-primary outcomes
The co-primary outcomes are changes in body weight and 
the KOOS pain subscale from baseline (week 0) to the 
last visit in the main trial period (week 52).
Confirmatory secondary outcomes
The confirmatory secondary outcomes are changes in 
the KOOS symptom, ADL, sport and recreation and 
HRQoL subscales, the WOMAC pain, stiffness and func-
tion subscales, the total score and subscales in the ICOAP 
questionnaire, BMI, waist circumference or the waist/
hip ratio from baseline (week 0) to the last visit in the 
main trial period (week 52). Moreover, the proportion of 
patients with ≥5% or ≥10% weight loss at the last visit in 
the main trial period (week 52) also constitutes confirma-
tory secondary outcomes.
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Supportive secondary outcomes
The supportive secondary outcomes are changes in 
biomarkers (CRP, HbA1c, FPG, ALT, LDL, HDL, TG and 
TC), BP, resting heart rate, the impact of weight on 
quality of life (IWQoL-Lite), treatment-related impact 
on quality of life (TRIM-Weight) and the general health 
status (SF-36) from baseline (week 0) to the last visit in 
the main trial period (week 52). Changes in proportion 
of patients meeting the criteria for metabolic syndrome 
or prediabetes from week 0 to 52 as well as the propor-
tion of patients classified as responders (the O-O responder 
criteria) at the last visit in the main trial period (week 52) also 
constitutes confirmatory secondary outcomes.
Safety outcomes
The safety outcomes include the incidence of adverse 
events (AEs), suicidal behaviour and/or ideation 
(C-SSRS), depression (PHQ-9), binge eating (BES) and 
measures outside reference limits for haemoglobin, 
thrombocytes, leucocytes, differential cell count, creat-
inine and electrolytes (±2 SD) and for ALT and CRP 
(+150%).
data management
The collection, preservation and dissemination of the 
clinical data is specified in this clinical trial protocol and 
abide by the standard requirements for GCP-compliant 
data management in clinical trials.
The source data and documents, eCRF, protocol and 
amendments, drug accountability forms, correspon-
dence, patient identification list, informed consent forms 
and other essential GCP documents will be retained for 
at least 10 years after the study is completed at the study 
site. Data entries are quality ensured by double data entry, 
classification of data type (ie, text and numbers) and/or 
range checks for data values.
All data collected during this project will be managed 
and quality certified by the Parker Institutes data manage-
ment team, composed by the primary investigator, a data 
manager and a chief administrator. This team is respon-
sible for ensuring data completeness and accuracy as well 
as source data verification. The latter will be performed 
by the monitor and the relevant investigators. The team is 
also responsible for ensuring operations of a secure data-
base established for the collection of clinical data collected 
via the eCRF platform through a secure connection. All 
data obtained during the study will be documented in the 
individual eCRFs. Reasons for any missing data will be 
noted in the database, and logging and tracking of data 
changes will be documented.
randomisation
Participants will be randomised to treatment daily with 
liraglutide 3 mg/day or liraglutide placebo 3 mg at week 
0, that is, after the initial 8-week IDI period. Participants 
will be randomised in a 1:1 manner to receive either 
3 mg/day liraglutide or identically appearing placebo; 
stratified randomisation will be based on gender (male 
vs female), age (<60 years vs ≥60 years) and obesity class 
(BMI <40 vs ≥40 kg/m2) status at trial enrolment (week 
−8). A computer-generated randomisation sequence will 
be produced using SAS PROC PLAN to generate the 
eight randomisation schedules before any participant is 
enrolled, allocating participants in permuted blocks of 
two to six to the daily liraglutide 3 mg/day or placebo 
group (1:1). The randomisation sequence is entered into 
the eCRF by a data manager.
Allocation concealment and blinding
The trial uses a computer-generated allocation process 
in which the patient identifier is coupled to one of the 
experimental arms when the physician clicks on the 
‘randomisation button’, appearing at visit T0 in the eCRF 
system. On allocation to one of the two experimental 
arms the patient identifier is automatically coupled to 
specific pens, each of them labelled by a single and unique 
Dispensing Unit Number. The entire process is blinded 
for all investigators, clinical, academic and administrative 
trial personnel.
Unblinding will only take place in exceptional circum-
stances when knowledge of the actual treatment is essen-
tial for further management of the patient. If unblinding 
is deemed necessary, the investigator will activate a data 
solution, within the eCRF, build for this specific purpose 
and controlled by an independent data manager and 
the chief administrator. The actual allocation will not be 
disclosed to the patient and/or other study personnel 
including other site personnel, monitors, corporate spon-
sors or project office staff.
sample size and power considerations
The co-primary outcomes are changes in body weight 
and KOOS pain from randomisation to the end of the 
trial, 52 weeks after randomisation. The sample size of 
150 is designed to provide a reasonable power (>80%) to 
detect a 5 kg difference in body weight change between 
the groups, and an 8-units difference in the KOOS pain. 
All power and sample size analyses were conducted using 
'SAS Power and Sample Size', V.3.1 (SAS Institute, Cary, 
North Carolina, USA):
 ► Body weight: for a two-sample pooled t-test of a 
normal mean difference with a two-sided significance 
level of 0.05 (p<0.05), assuming a common SD of 
10 kg (conservatively estimated based on our previous 
weight loss trial in this patient population22), a sample 
size of 75 per group, has a power of 92% to detect a 
mean difference of 5.5 kg in the group mean change 
in body weight.
 ► KOOS pain: for a two-sample pooled t-test of a 
normal mean difference with a two-sided significance 
level of 0.05 (p<0.05), assuming a common SD of 15 
KOOS points, a sample size of 75 patients per group 
has a power of 90% to detect a mean difference in 
the group mean changes of 8 KOOS points (corre-
sponding to a moderate Cohen’s effect size of 0.5).
The combined power for the two end points is 83%.
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statistical methods
The prespecified efficacy analyses will be based on the 
data from the full-analysis set, that is, the intention-to-treat 
(ITT) population—including all participants who are 
randomised and assessed at baseline. In case of missing 
data at week 52, the observation from enrolment will be 
carried forward in case of missing data in the ITT popu-
lation. The safety analysis set includes all patients who are 
randomly assigned to a trial group and have had expo-
sure to a trial drug (ie, liraglutide 3 mg/day or placebo). 
This trial does not plan for any interim analyses.
The primary analysis will be the comparison between 
liraglutide and placebo using an analysis of covariance 
(ANCOVA) model with treatment, gender, age and 
obesity stratification as fixed effects and with adjustment 
for the level at baseline as a covariate. From this model, the 
observed differences in weight change and KOOS pain 
change between liraglutide treatment and placebo will be 
estimated together with the associated 95% CI and the 
p value corresponding to the test of the hypothesis of no 
difference between treatments (ie, the null hypothesis).
To establish the efficacy of liraglutide 3 mg/day 
compared with placebo in patients with overweight or 
obesity and knee OA, inducing and maintaining weight 
loss and pain relief over 52 weeks, end points are tested 
in a hierarchical manner in the order in which the 
end points are presented. Liraglutide 3 mg/day will be 
considered statistically significantly better than liraglu-
tide placebo 3 mg/day placebo with respect to change in 
body weight if the null hypothesis is rejected (p<0.05). 
But, overall, liraglutide 3 mg/day will only be confirmed as 
statistically significantly better than placebo with respect 
to change in KOOS pain subscale, if it is also statistically 
significantly better with respect to change in body weight.
Categorical changes for dichotomous end points will be 
analysed with the use of logistic regression with the same 
fixed effects and covariates as the respective ANCOVA. 
Sensitivity analyses will be performed to assess the robust-
ness of the primary analyses, including ‘per-protocol’ 
scenarios, repeated-measures linear mixed models and 
multiple imputation techniques.
Management
The project management team consists of the Primary 
Investigator, Dr Henrik Rindel Gudbergsen who is 
responsible for the execution of the project, the Spon-
sor-Investigator Professor Henning Bliddal who is respon-
sible for the overall scientific planning of the project 
and Chief Administrator Claus Bomhoff who is respon-
sible for administrative and financial tasks. The steering 
committee (SC), led by the Primary Investigator, is the 
principal management body with respect to the opera-
tional and scientific facets of this trial. Members of the 
SC are the investigators involved in the development of 
this protocol and include HG (chairman), HB (sponsor), 
MH, EEW, HB, RC, MB, FKKK, AA, MUR and LEK. The 
SC will ensure trial resources, schedule all trial-related 
activities and ensure execution of the trial.
The independent ethics committee (ICE) monitors 
any safety and/or ethical concerns arising during the 
project and to advise the SC. The members of the ICE are 
Lennart Jacobsson, Professor in Rheumatology, Depart-
ment of Rheumatology, Sahlgrenska University Hospital, 
Gothenburg, Sweden and Karl Agner Kristensen MD, 
PhD, Specialist in Obstetrics and Gynaecology, Depart-
ment of Obstetrics and Gynaecology, Lund University 
Hospital, Lund, Sweden.
Patient and public involvement
Via a formal review process, the authors retrieved input 
from an appointed knee OA patient advisor in a discus-
sion focusing on the development of hypotheses, inter-
ventions and outcomes related to this study. The design 
of the study was not discussed with patients, whereas the 
burden of the study was assessed by all patients via an 
initial appraisal of their motivation to participate in the 
study and via a thorough description of the study in rela-
tion to the signing of the informed consent.
The institute’s patient board and the appointed knee 
OA advisor were also involved in proposing potential 
routes for communication regarding recruitment of 
patients, including websites and patient associations. 
Patients will be informed, via dialogue and a briefing 
document, that they may access results on an individual 
basis throughout the trial and that the study personnel 
will engage in presenting the overall results for each indi-
vidual patient once the trial is complete. On trial comple-
tion, patients will also be invited to a meeting where the 
project results are presented in a manner that is under-
standable by laymen.
EtHICs And dIssEMInAtIon
The investigator will monitor each participant for clin-
ical and laboratory evidence of AEs on a routine basis 
throughout the trial. AEs, whether in response to a query, 
observed by site personnel or reported spontaneously by 
the participant, will be recorded. The investigator will 
assess and record any AE in detail, including the date of 
onset, description, severity, duration and outcome, rela-
tionship of the AE to trial drug and any action(s) taken.
The treatment and investigations in this trial are asso-
ciated with minimal discomfort for the participants. 
The injection is practically pain-free but may leave a 
small haemorrhage, resolving spontaneously within a 
few days in the vast majority of patients. Less commonly, 
the patients may experience abdominal pain, insomnia, 
reflux, gastritis and dizziness. Uncommon AEs comprise 
dehydration, tachycardia, pancreatitis, cholecystitis, urti-
carial and malaise.
When collecting blood samples some participants may 
experience minor discomfort when the needle penetrates 
the skin, and rarely a small bleeding occurs. The planned 
radiographs will be identical and obtained at the same 
frequency as recommended in the current care model at 
the involved outpatient clinics.
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The participants included in the planned clinical trial 
will not receive any financial compensation. Neither the 
sponsor-investigator nor any of the other members of 
the project group has financial interest in neither the 
conduct nor the results of the trial.
All participants will be covered by a patient-insur-
ance, according to national requirements and common 
conduct, during the conduction of the clinical trials.
The successful planning and conduction of this trial 
may provide the basis for a significant improvement in 
the disease management of the many overweight citizens 
impacted by knee OA.
The number and timing of visits has been outlined to 
ensure observation of any safety issues as well as thor-
ough management of medication handout and usage 
throughout the study.
Based on involvement of patients as well as the existing 
experience within the field of weight loss and knee OA 
management, the study design is considered to be accept-
able for patients as well as feasible to implement. Never-
theless, this study will deliver comprehensive insights into 
the practicality and acceptability of the interventions 
studied in this specific context, and provide valuable 
information regarding the generalisability of the inter-
ventions in question.
At the end of the trial, one or more manuscripts will 
be prepared for publication in peer-reviewed journals. 
The manuscripts will be written in accordance with the 
Consolidated Standards of Reporting Trials statement. 
The manuscripts will include positive, negative as well 
as inconclusive results. In addition, the results from the 
trial will be presented as posters or oral presentations at 
national and/or international conferences.
Novo Nordisk and The Cambridge Weight Plan had 
no influence on the study design, nor will they have any 
influence on the analyses and interpretation of data or 
the writing of manuscripts/abstracts based on trial data. 
Novo Nordisk and The Cambridge Weight Plan will be 
given 4 weeks to review any manuscript/abstract or other 
means intended for publication or presentation of the 
data. All authors will qualify for authorship according 
to International Committee of Medical Journal Editors, 
1997, and must have participated sufficiently in the work 
to take public responsibility for the content.
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